The specific objectives and responsibilities of the Administrative Core are: (1) Enter patients with MDS into the Leukemia Database and ensure that patients go on the appropriate protocols; (2) Assist Core B in sample acquisition and ensure that results from samples sent to laboratory investigators in Projects 2-5 are reported back; (3) Maintain the current FileMan database and facilitate the transition to the new Oracle-based database (4) Organize meetings of Program Project personnel and of Internal and External Advisory Committees (5) Coordinate reports and manuscripts resulting from the Program Project; (6) Monitor expenditures for all Projects and Cores. For purposes of registration and follow-up, we will use established routines in the Leukemia Department at MDACC. These are overseen by experienced personnel and have been the basis for many publications. We will track the number of samples received at the various program project laboratories relative to the number of patients with MDS seen in the Leukemia Department at MDACC, and the number of samples analyzed by these laboratories and entered into the program project database within two months of receipt. The existing leukemia database contains pre-treatment, response, and survival data on over 2,000 patients with MDS. Drs. Estey and Kantarjian will lead the Administrative Core providing leadership and general administration of all activities related to the P01.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA108631-05
Application #
7884244
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-06-01
Budget End
2010-05-31
Support Year
5
Fiscal Year
2009
Total Cost
$136,593
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Kahn, Josephine D; Miller, Peter G; Silver, Alexander J et al. (2018) PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood 132:1095-1105
Sievers, Quinlan L; Petzold, Georg; Bunker, Richard D et al. (2018) Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362:
Fink, Emma C; McConkey, Marie; Adams, Dylan N et al. (2018) CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood 132:1535-1544
Tothova, Zuzana; Krill-Burger, John M; Popova, Katerina D et al. (2017) Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. Cell Stem Cell 21:547-555.e8
Ajore, Ram; Raiser, David; McConkey, Marie et al. (2017) Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. EMBO Mol Med 9:498-507
Krönke, Jan; Fink, Emma C; Hollenbach, Paul W et al. (2015) Lenalidomide induces ubiquitination and degradation of CK1? in del(5q) MDS. Nature 523:183-188
Yamazaki, Jumpei; Jelinek, Jaroslav; Lu, Yue et al. (2015) TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia. Cancer Res 75:2833-43
Malouf, Gabriel G; Zhang, Jianping; Yuan, Ying et al. (2015) Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 9:32-43
Fink, Emma C; Ebert, Benjamin L (2015) The novel mechanism of lenalidomide activity. Blood 126:2366-9
Lindsley, R Coleman; Mar, Brenton G; Mazzola, Emanuele et al. (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367-76

Showing the most recent 10 out of 80 publications